Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.57 |
| ▸ | INSR | P06213 | 7/20 | 0.57 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.53 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769118 | 0.93 | ULK1 (0.66) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3756752 | 0.90 | ALK (0.56) | ULK1ALKZAP70EGFRGSK3A | |
| SCHEMBL3756737 | 0.89 | PLK1 (0.61) | ULK1ALKINSRZAP70EGFR | |
| SCHEMBL3763429 | 0.88 | ALK (0.60) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3761418 | 0.86 | ULK1 (0.64) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3762506 | 0.85 | ULK1 (0.75) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3758981 | 0.83 | ALK (0.56) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3766371 | 0.83 | PLK1 (0.62) | ULK1ALKINSRZAP70EGFR | |
| SCHEMBL3766662 | 0.81 | PLK1 (0.60) | ULK1ALKINSRZAP70LRRK2 | |
| SCHEMBL3758454 | 0.80 | ALK (0.67) | ULK1ALKINSRZAP70LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | claimed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | ULK1 281/4885ALK 397/4885INSR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.